US5709854A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tissue formation by injecting a cell-polymeric solution that gels in vivo
Assignee: Boston Children's Hospital
•
Filing: 1993-04-30
•
Granted: 1998-01-20
•
Expires: 2013-04-30
Abstract
Abstract A cell-polymeric solution is injected into an animal where the polymer crosslinks to form a polymeric hydrogel containing dispersed cells and the cells form new tissue in the animal. The polymer is biodegradable and is a natural polymer such as alginate or a synthetic polymer. The cells are chondrocytes, osteoblasts, muscle cells, fibroblasts or cells acting primarily to synthesize, secret or metabolize materials. Crosslinking of the polymer results from using cations or anions, altering the pH or changing the temperature. A polyion such as polyethyleneimine or polylysine can be added before injection to stabilize the polymeric hydrogel. A kit for tissue formation is provided by combining the cell-polymeric solution with a means for injecting the solution into an animal.
Inventors
- 👤 Linda Griffith-Cima
- 👤 Anthony Atala
- 👤 Charles A. Vacanti
- 👤 Keith T. Paige
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:07
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61L27/383; A61F; A61F2/00; A61F2/0004; A61F2/0031; A61F2/0036; A61F2/02; A61K; A61K35/00; A61K35/12; A61K35/34; A61L27/14; A61L27/20; A61L27/22; A61L27/222; A61L27/24; A61L27/3826; A61L27/3839; A61L27/3843; A61L27/3847; A61L27/3852; A61L27/3882; A61L27/50; A61L27/52; C; C12; C12N; C12N5/00; C12N5/0068; A61F2/0059; A61F2310/00; A61F2310/00005; A61F2310/00365; A61F2310/00383; A61L2400/00; A61L2400/06
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
127 words
A method for injecting a cell suspension into an animal to form tissue within the animal comprising forming a cell-polymeric solution by mixing a solution of a biodegradable, biocompatible natural or synthetic organic polymer, wherein the polymer is capable of being cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel, with dissociated cells, wherein the cells are selected from the group consisting of chondrocytes, osteoblasts, muscle cells, fibroblasts, and cells acting primarily to synthesize, secret or metabolize materials, to form an injectable cell-polymeric solution having cells dispersed therein and injecting the cell-polymeric solution into the animal which crosslinks to form a polymeric hydrogel having cells dispersed therein inside the animal, whereby the cells form tissue.
Claim 2
Independent Claim
127 words
A method for injecting a cell suspension into an animal to form tissue within the animal comprising forming a cell-polymeric solution by mixing a solution of a biodegradable, biocompatible natural or synthetic organic polymer, wherein the polymer is capable of being cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel, with dissociated cells, wherein the cells are selected from the group consisting of chondrocytes, osteoblasts, muscle cells, fibroblasts, and cells acting primarily to synthesize, secret or metabolize materials, to form an injectable cell-polymeric solution having cells dispersed therein and injecting the cell-polymeric solution into the animal which crosslinks to form a polymeric hydrogel having cells dispersed therein inside the animal, whereby the cells form tissue.
Claim 3
Dependent Claim
19 words
The method of claim 1 wherein crosslinking of the polymer solution is initiated prior to implantation in the animal.
Claim 4
Dependent Claim
22 words
The method of claim 1 wherein crosslinking of the polymer solution is initiated after the polymer solution is injected into the animal.
Claim 5
Dependent Claim
30 words
The method of claim 1 wherein the polymer is selected from the group consisting of alginate, polyphosphazines, polyethylene-oxide-polypropylene glycol block copolymers, poly(acrylic acids), poly(methacrylic acids, poly(vinyl acetate), and sulfonated polymers.
Claim 6
Dependent Claim
21 words
The method of claim 4 wherein the polymer solution is crosslinked by using ions, altering the pH or changing the temperature.
Claim 7
Dependent Claim
53 words
The method of claim 1 wherein the polymer solution is crosslinked by interaction with cations selected from the group consisting of copper, calcium, aluminum, magnesium, strontium, barium, tin, and di-, tri- and tetrafunctional organic cations; or anions selected from the group consisting of low molecular weight dicarboxylic acids, sulfate ions and carbonate ions.
Claim 8
Dependent Claim
23 words
The method of claim 4 wherein the hydrogel is further stabilized by cross-linking with a polyion added to the cell-polymeric solution before injection.
Claim 9
Dependent Claim
29 words
The method of claim 1 wherein the cells are selected from the group consisting of chondrocytes, muscle cells, fibroblasts, and cells acting primarily to synthesize, secret or metabolize materials.
Claim 10
Dependent Claim
12 words
The method of claim 1 wherein the polymer is a synthetic polymer.
Claim 11
Dependent Claim
103 words
A kit for formation of tissue at a site in a patient comprising An injectable cell-polymeric solution comprising a biodegradable, biocompatible natural or synthetic organic polymer, wherein the polymer crosslinks after injection via covalent, ionic, or hydrogen bonds to create a polymeric hydrogel having dispersed therein dissociated heterologous cells, wherein the cells are selected from the group consisting of chondrocytes, osteoblasts, muscle cells, fibroblasts, and cells acting primarily to synthesize, secret or metabolize materials, the hydrogel consisting of the injected cell-polymeric solution, in combination with means for injecting the cell-polymeric solution into the site in the patient where tissue is to be formed.
Claim 12
Dependent Claim
103 words
A kit for formation of tissue at a site in a patient comprising An injectable cell-polymeric solution comprising a biodegradable, biocompatible natural or synthetic organic polymer, wherein the polymer crosslinks after injection via covalent, ionic, or hydrogen bonds to create a polymeric hydrogel having dispersed therein dissociated heterologous cells, wherein the cells are selected from the group consisting of chondrocytes, osteoblasts, muscle cells, fibroblasts, and cells acting primarily to synthesize, secret or metabolize materials, the hydrogel consisting of the injected cell-polymeric solution, in combination with means for injecting the cell-polymeric solution into the site in the patient where tissue is to be formed.
Claim 13
Dependent Claim
12 words
The kit of claim 10 wherein the polymer is a synthetic polymer.
References Cited (Backward Citations)
US2609347A
Cited
US2664366A
Cited
US2664367A
Cited
US2659935A
Cited
US2653917A
Cited
US2846407A
Cited
US3880991A
Cited
US4069307A
Cited
US3960150A
Cited
US4026304A
Cited
US3883393A
Cited
US3826241A
Cited
US4450150A
Cited
US3974526A
Cited
US3902497A
Cited
US4192827A
Cited
US3949073A
Cited
US4280954A
Cited
US4186448A
Cited
US4391797A
Cited
US4141087A
Cited
US4205399A
Cited
US4137921A
Cited
US4304591A
Cited
US4277582A
Cited
US4239664A
Cited
US4243775A
Cited
US4456687A
Cited
US4391909A
Cited
US4352883A
Cited
US4304866A
Cited
US4348329A
Cited
US4347847A
Cited
US4563490A
Cited
US4576608A
Cited
US4675189A
Cited
US4416986A
Cited
US4546500A
Cited
US4438198A
Cited
US4431428A
Cited
US4446234A
Cited
US4505266A
Cited
US4485096A
Cited
US4439152A
Cited
US4545082A
Cited
US4520821A
Cited
US4495174A
Cited
US4440921A
Cited
US4544516A
Cited
US4673566A
Cited
US4689293A
Cited
US4806355A
Cited
US4803168A
Cited
US4609551A
Cited
US4891225A
Cited
US4637931A
Cited
US4868121A
Cited
US4681763A
Cited
US4853324A
Cited
US4721096A
Cited
WO1987006120A1
Cited
US4880622A
Cited
US4757128A
Cited
US5041138A
Cited
EP0282746A1
Cited
US4963489A
Cited
WO1989000413A1
Cited
US4846135A
Cited
EP0339607A2
Cited
US5032508A
Cited
US4988761A
Cited
EP0361957A1
Cited
US4946938A
Cited
WO1991001720A1
Cited
US5354736A
Cited
WO1992006702A1
Cited
WO1992019195A1
Cited
WO1994021299A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-01-19 | 2001-07-21 | 2002-01-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-01-19 | 2005-07-21 | 2006-01-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-01-19 | 2009-07-21 | 2010-01-20 | $7700.00 | Window Closed / Lapsed |